Drug-Induced Acneiform Eruption

Abstract

Drug-induced acne is a specific subset of acne that usually has some specific features, namely a monomorphic pattern, an unusual location of the lesions beyond the seborrheic areas, an unusual age of onset, a resistance to conventional acne therapy and, of course, the notion of a recent drug introduction. Many drugs can be responsible for such a clinical pattern. Corticosteroids, neuropsychotherapeutic drugs, antituberculosis drugs, and immunomodulating molecules are the more classical drugs associated with induced acne. Recently, new drugs, mainly targeted therapy in the field of oncology, such as epidermal growth factor receptor inhibitors, have been associated with an increased frequency of this adverse effect. Disruption of the culprit drug is rarely mandatory in cases of drug-induced acne. Close cooperation between the dermatologist and medical staff in charge of the patient is an important challenge to achieve optimal management of the initial disease.

This is a preview of subscription content, access via your institution.

Table I
Table II
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Table III
Table IV

References

  1. 1.

    Hitch JM. Acneform eruptions induced by drugs and chemicals. JAMA 1967; 200: 879–80

    PubMed  CAS  Article  Google Scholar 

  2. 2.

    Kligman AM, Plewig G. Classification of acne. Cutis 1976; 17: 520–2

    PubMed  CAS  Google Scholar 

  3. 3.

    Brunner MS, Riddell Jr JM, Best WR. Cutaneous side effects of ACTH, cortisone, and pregnenolone therapy. J Invest Dermatol 1951; 16: 205–9

    PubMed  CAS  Google Scholar 

  4. 4.

    Sullivan M, Zeligman I. Acneform eruption due to corticotropin. AMA Arch Dermatol 1956; 73: 133–41

    CAS  Article  Google Scholar 

  5. 5.

    Plewig G, Kligman AM. Induction of acne by topical steroids. Arch Dermatol Forsch 1973; 247: 29–52

    PubMed  CAS  Google Scholar 

  6. 6.

    Fung MA, Berger TG. A prospective study of acute-onset steroid acne associated with administration of intravenous corticosteroids. Dermatology 2000; 200: 43–4

    Article  Google Scholar 

  7. 7.

    Monk B, Cunlife WJ, Layton AM, et al. Acne induced by inhaled corticosteroids. Clin Exp Derm 1993; 1: 148–50

    Article  Google Scholar 

  8. 8.

    Guillot B. Adverse skin reactions to inhaled corticosteroids. Expert Opin Drug Saf 2002; 1: 325–9

    PubMed  CAS  Article  Google Scholar 

  9. 9.

    Bedane C, Souyri N. Induced acne. Ann Dermatol Venereol 1990; 117: 53–8

    PubMed  CAS  Google Scholar 

  10. 10.

    Hurwitz RM. Steroid acne. J Am Acad Dermatol 1989; 21: 1179–81

    PubMed  CAS  Article  Google Scholar 

  11. 11.

    Fyrand O, Fiskaadal HJ, Trygstad O. Acne in pubertal boys undergoing treatment with androgens. Acta Derm Venereol 1992; 72: 148–9

    PubMed  CAS  Google Scholar 

  12. 12.

    Heydenreich G. Testosterone and anabolic steroids and acne fulminans. Arch Dermatol 1989; 125: 571–2

    PubMed  CAS  Article  Google Scholar 

  13. 13.

    Melnik B, Jansen T, Grabbe S. Abuse of anabolic-androgenic steroids and bodybuilding acne: an underestimated health problem. J Dtsch Dermatol Ges 2007; 5: 110–7

    PubMed  Article  Google Scholar 

  14. 14.

    Gerber PA, Kukova G, Meller S, et al. The dire consequences of doping. Lancet 2008; 372: 1544

    Article  Google Scholar 

  15. 15.

    Yildizbas B, Sahin HG, Kolusari A, et al. Side effects and acceptability of Implanon: a pilot study conducted in eastern Turkey. Eur J Contracept Reprod Health Care 2007; 12: 248–52

    PubMed  CAS  Article  Google Scholar 

  16. 16.

    Funk S, Miller MM, Mishell Jr DR, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005; 71: 319–26

    PubMed  CAS  Article  Google Scholar 

  17. 17.

    Gezginc K, Balci O, Karatayli R, et al. Contraceptive efficacy and side effects of Implanon. Eur J Contracept Reprod Health Care 2007; 12: 362–5

    PubMed  CAS  Article  Google Scholar 

  18. 18.

    Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril 2009; 91: 1646–53

    PubMed  Article  Google Scholar 

  19. 19.

    Cohen EB, Rossen NN. Acne vulgaris in connection with the use of progestagens in a hormonal IUD or a subcutaneous implant [in Dutch]. Ned Tijdschr Geneeskd 2003; 147: 2137–9

    PubMed  CAS  Google Scholar 

  20. 20.

    Ilse JR, Greenberg HL, Bennett DD. Levonorgestrel-releasing intrauterine system and new-onset acne [letter]. Cutis 2008; 82: 158

    PubMed  Google Scholar 

  21. 21.

    Greenberg RD. Acne vulgaris associated with antigonadotropic (Danazol) therapy. Cutis 1979; 24: 431–3

    PubMed  CAS  Google Scholar 

  22. 22.

    Thioly-Bensoussan D, Charpentier A, Triller R, et al. Iatrogenic acne caused by amineptin (Survector): apropos of 8 cases. Ann Dermatol Venereol 1988; 115: 1177–80

    PubMed  CAS  Google Scholar 

  23. 23.

    Grupper C. New iatrogenic acne: acne caused by amineptin (Survector). Ann Dermatol Venereol 1988; 115: 1174–6

    PubMed  CAS  Google Scholar 

  24. 24.

    Vexiau P, Gourmel B, Husson C, et al. Severe lesions of acne type induced by chronic amineptin poisoning: apropos of 6 cases. Ann Dermatol Venereol 1988; 115: 1180–2

    PubMed  CAS  Google Scholar 

  25. 25.

    Teillac D, Weber MJ, Lowenstein W, et al. Acne caused by Survector [in French]. Ann Dermatol Venereol 1988; 115: 1183–4

    PubMed  CAS  Google Scholar 

  26. 26.

    Lévigne V, Faisant M, Mourier CG, et al. Monstrous acne in the adult: inducer role of Survector? Ann Dermatol Venereol 1988; 115: 1184–5

    PubMed  Google Scholar 

  27. 27.

    Vexiau P, Gourmel B, Julien R, et al. Severe acne-like lesions caused by amineptine overdose [letter]. Lancet 1988; 1: 585

    PubMed  CAS  Article  Google Scholar 

  28. 28.

    Vexiau P, Gourmel B, Castot A, et al. Severe acne due to chronic amineptine overdose. Arch Dermatol Res 1990; 282: 103–7

    PubMed  CAS  Article  Google Scholar 

  29. 29.

    Huet P, Dandurand M, Joujoux JM, et al. Acne induced by amineptin: adnexal toxiderma. Ann Dermatol Venereol 1996; 123: 817–20

    PubMed  CAS  Google Scholar 

  30. 30.

    Duriot JF, Dutertre JP, Grenier JM, et al. Amineptin dependence and iatrogenic acne: review of the literature apropos of a case. Ann Med Psychol (Paris) 1991; 149: 795–7

    CAS  Google Scholar 

  31. 31.

    Farella V, Sberna F, Knöpfel B, et al. Acne-like eruption caused by amineptine. Int J Dermatol 1996; 35: 892–3

    PubMed  CAS  Article  Google Scholar 

  32. 32.

    Bettoli V, Trimurti S, Lombardi AR, et al. Acne due to amineptine abuse. J Eur Acad Dermatol Venereol 1998; 10: 281–3

    PubMed  CAS  Article  Google Scholar 

  33. 33.

    Grimalt R, Mascaró-Galy JM, Ferrando J, et al. Guess what? Macronodular iatrogenic acne due to amineptine. Eur J Dermatol 1999; 9: 491–2

    PubMed  CAS  Google Scholar 

  34. 34.

    De Gálvez Aranda MV, Sánchez PS, Alonso Corral MJ, et al. Acneiform eruption caused by amineptine: a case report and review of the literature. J Eur Acad Dermatol Venereol 2001; 15: 337–9

    PubMed  Google Scholar 

  35. 35.

    Ponte CD. Maprotiline induced acne. Am J Psychiatry 1982; 139: 141

    PubMed  CAS  Google Scholar 

  36. 36.

    Ossofsky J. Amenorrhea in endogenous depression. Int Pharmacopsychiatry 1974; 9: 100–8

    PubMed  CAS  Google Scholar 

  37. 37.

    Kusumi Y. A cutaneous side effect of lithium: report of two cases. Dis Nerv Syst 1971; 32: 853–4

    PubMed  CAS  Google Scholar 

  38. 38.

    Ruíz-Maldonado R, Pérez de Francisco C, Tamayo L. Lithium dermatitis [letter]. JAMA 1973; 224: 1534

    PubMed  Article  Google Scholar 

  39. 39.

    Yoder FW. Acneiform eruption due to lithium carbonate [letter]. Arch Dermatol 1975; 111: 396–7

    PubMed  CAS  Article  Google Scholar 

  40. 40.

    Sarantidis D, Waters B. A review and controlled study of cutaneous conditions associated with lithium carbonate. Br J Psychiatry 1983; 143: 42–50

    PubMed  CAS  Article  Google Scholar 

  41. 41.

    Yeung CK, Chan HH. Cutaneous adverse effects of lithium: epidemiology and management. Am J Clin Dermatol 2004; 5: 3–8

    PubMed  Article  Google Scholar 

  42. 42.

    Heng MC. Lithium carbonate toxicity: acneiform eruption and other manifestations. Arch Dermatol 1982; 118: 246–8

    PubMed  CAS  Article  Google Scholar 

  43. 43.

    Jenkins RB, Ratner AC. Diphenyl hydantoin and acne [letter]. N Engl J Med 1972; 287: 148

    PubMed  CAS  Google Scholar 

  44. 44.

    Frentz G. Acne and phenytoin [in Danish]. Ugeskr Laeger 1977; 139: 338–9

    Google Scholar 

  45. 45.

    Norris JF, Cunliffe WJ. Phenytoin-induced gum hypertrophy improved by isotretinoin. Int J Dermatol 1987; 26: 602–3

    PubMed  CAS  Article  Google Scholar 

  46. 46.

    Gunwald MH, Ben-Dor D, Livni E, et al. Acne keloidalis-like lesions on the scalp associated with antiepileptic drugs. Int J Dermatol 1990; 29: 559–61

    Article  Google Scholar 

  47. 47.

    Nielsen JN, Licht RW, Fogh K. Two cases of acneiform eruption associated with lamotrigine. J Clin Psychiatry 2004; 65: 1720–2

    PubMed  Article  Google Scholar 

  48. 48.

    Hesse S, Berbis P, Lafforgue P, et al. Acne and enthesiopathy during antiepileptic treatment. Ann Dermatol Venereol 1992; 119: 655–8

    PubMed  CAS  Google Scholar 

  49. 49.

    Greenwood R, Fenwick PB, Cunliffe WJ. Acne and anti-convulsants. Br Med J 1983; 287: 1669–70

    CAS  Article  Google Scholar 

  50. 50.

    Mishra B, Praharaj SK, Prakash R, et al. Aripiprazole-induced acneiform eruption. Gen Hosp Psychiatry 2008; 30: 479–81

    PubMed  Article  Google Scholar 

  51. 51.

    Warnock JK, Morris DW. Adverse cutaneous reactions to antidepressants. Am J Clin Dermatol 2002; 3: 329–39

    PubMed  Article  Google Scholar 

  52. 52.

    Ade G. Poussées d’eczéma séborrhéique ou acné iforme probablement consécutives áun traitement ála vitamine B12 [letter]. Dermatologica 1958; 116: 366

    Article  Google Scholar 

  53. 53.

    Dugois P, Amblard P, Imbert R, et al. Acne due to vitamin B12 [in French]. Bull Soc Fr Dermatol Syphiligr 1969; 76: 382–3

    PubMed  CAS  Google Scholar 

  54. 54.

    Puissant A, Vanbremeersch F, Monfort J, et al. A new iatrogenic dermatosis: acne caused by vitamin B12 [in French]. Bull Soc Fr Dermatol Syphiligr 1967; 74: 813–5

    PubMed  CAS  Google Scholar 

  55. 55.

    Dupré A, Albarel N, Bonafe JL, et al. Vitamin B-12 induced acnes. Cutis 1979; 24: 210–1

    PubMed  Google Scholar 

  56. 56.

    Sheretz EF. Acneiform eruption due to ‘megadose’ vitamins B6 and B12. Cutis 1991; 48: 119–20

    Google Scholar 

  57. 57.

    Braun-Falco O, Lincke H. The problem of vitamin B6/B12 acne: a contribution on acne medicamentosa. MMW Munch Med Wochen Schr 1976; 118: 155–60

    CAS  Google Scholar 

  58. 58.

    Blatt J, Lee PA. Severe acne and hyperandrogenemia following dactinomycin. Med Pediatr Oncol 1993; 5: 373–4

    Article  Google Scholar 

  59. 59.

    Schmoeckel C, von Liebe V. Acneiformexanthema caused by azathioprine [in German]. Hautarzt 1983; 34: 413–5

    PubMed  CAS  Google Scholar 

  60. 60.

    Bencini PL, Montagnino G, Crosti C, et al. Cutaneous lesion in 67 cyclosporin-treated renal transplant recipients. Dermatologica 1986; 172: 24–30

    PubMed  CAS  Article  Google Scholar 

  61. 61.

    Strahan JE, Burch JM. Cyclosporine-induced infantile nodulocystic acne. Arch Dermatol 2009; 145: 797–9

    PubMed  Article  Google Scholar 

  62. 62.

    Richter A, Beideck S, Bender W, et al. Epidermal cysts and folliculitis caused by cyclosporin A [in German]. Hautarzt 1993; 44: 521–3

    PubMed  CAS  Google Scholar 

  63. 63.

    el-Shahawy MA, Gadallah MF, Massry SG. Acne: a potential side effect of cyclosporine A therapy. Nephron 1996; 72: 679–82

    PubMed  CAS  Article  Google Scholar 

  64. 64.

    Carnero L, Silvestre JF, Guijarro J, et al. Nuchal acne keloidalis associated with cyclosporin. Br J Dermatol 2001; 144: 429–30

    PubMed  CAS  Article  Google Scholar 

  65. 65.

    Bunker CB, Rustin MH, Dowd PM. Isotretinoin treatment of severe acne in posttransplant patients taking cyclosporine. J Am Acad Dermatol 1990; 22: 693–4

    PubMed  CAS  Article  Google Scholar 

  66. 66.

    Abel EA. Isotretinoin treatment of severe cystic acne in a heart transplant patient receiving cyclosporine: consideration of drug interactions [letter]. J Am Acad Dermatol 1991; 24: 511

    PubMed  CAS  Article  Google Scholar 

  67. 67.

    Hazen PE, Walker AE, Stewart JJ, et al. Successful use of isotretinoin in a patient on cyclosporine: apparent lack of toxicity [letter]. Int J Dermatol 1993; 32: 466

    PubMed  CAS  Article  Google Scholar 

  68. 68.

    Mahé E, Morelon E, Lechaton S, et al. Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol 2006; 55: 139–42

    PubMed  Article  Google Scholar 

  69. 69.

    Mahé E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005; 79: 476–82

    PubMed  Article  CAS  Google Scholar 

  70. 70.

    Lübbe J, Sorg O, Malé PJ, et al. Sirolimus-induced inflammatory papuleswith acquired reactive perforating collagenosis. Dermatology 2008; 216: 239–42

    PubMed  Article  CAS  Google Scholar 

  71. 71.

    Bakos L, Bakos RM. Focal acne during topical tacrolimus therapy for vitiligo. Arch Dermatol 2007; 143: 1223–4

    PubMed  Google Scholar 

  72. 72.

    Li JC, Xu AE. Facial acne during topical pimecrolimus therapy for vitiligo. Clin Exp Dermatol 2009; 34: e489–90

    Article  Google Scholar 

  73. 73.

    Bereston ES. Reactions to antituberculous drugs. J Invest Dermatol 1959; 33: 427–39

    PubMed  CAS  Article  Google Scholar 

  74. 74.

    Cohen LK, George W, Smith R. Isoniazid-induced acne and pellagra: occurrence in slow inactivators of isoniazid. Arch Dermatol 1974; 109: 377–81

    PubMed  CAS  Article  Google Scholar 

  75. 75.

    Oliwiecki S, Burton JL. Severe acne due to isoniazid. Clin Exp Dermatol 1988; 13: 283–4

    PubMed  CAS  Article  Google Scholar 

  76. 76.

    Holdiness MR. Adverse cutaneous reactions to antituberculosis drugs. Int J Dermatol 1985; 24: 280–5

    PubMed  CAS  Google Scholar 

  77. 77.

    Hesse PG. Antitubercular therapy and acneiform exanthema [in German]. Dermatol Wochenschr 1966; 152: 305–12

    PubMed  CAS  Google Scholar 

  78. 78.

    Nwokolo U. Acneiform lesions in combined rifampicin treatment in Africans [letter]. Br Med J 1974; 3: 473

    PubMed  CAS  Article  Google Scholar 

  79. 79.

    Levantine A, Almeyda J. Cutaneous reactions to antituberculosis drugs. Br J Dermatol 1972; 86: 651–5

    PubMed  CAS  Article  Google Scholar 

  80. 80.

    Papa CM. Acne and hidden iodides. Arch Dermatol 1976; 112: 55–6

    Article  Google Scholar 

  81. 81.

    Rosenberg FR, Einbinder J, Walzer RA, et al. Vegetating iododerma: an immunologic mechanism. Arch Dermatol 1972; 105: 900–5

    PubMed  CAS  Article  Google Scholar 

  82. 82.

    Inman P. Proceedings: iododerma. Br J Dermatol 1974; 91: 709–11

    PubMed  CAS  Article  Google Scholar 

  83. 83.

    Kint A, Van Herpe L. Iododerma. Dermatologica 1977; 155: 171–3

    PubMed  CAS  Google Scholar 

  84. 84.

    Heydenreich G, Larsen PO. Iododerma after high dose urography in an oliguric patient. Br J Dermatol 1977; 97: 567–9

    PubMed  CAS  Article  Google Scholar 

  85. 85.

    Belaïch S, Crickx B, Schwartz C, et al. Vegetating iododerma following lymphography. Ann Dermatol Venereol 1985; 112: 699–700

    PubMed  Google Scholar 

  86. 86.

    Wilkin JK, Strobel D. Iododerma occurring during thyroid protection treatment. Cutis 1985; 36: 335–7

    PubMed  CAS  Google Scholar 

  87. 87.

    Boudoulas O, Siegle RJ, Grimwood RE. Iododerma occurring after orally administered iopanoic acid. Arch Dermatol 1987; 123: 387–8

    PubMed  CAS  Article  Google Scholar 

  88. 88.

    Soria C, Allegue F, España A, et al. Vegetating iododerma with underlying systemic diseases: report of three cases. J Am Acad Dermatol 1990; 22: 418–22

    PubMed  CAS  Article  Google Scholar 

  89. 89.

    Vaillant L, Pengloan J, Blanchier D, et al. Iododerma and acute respiratory distress with leucocytoclastic vasculitis following the intravenous injection of contrast medium. Clin Exp Dermatol 1990; 15: 232–3

    PubMed  CAS  Article  Google Scholar 

  90. 90.

    Noonan MP, Williams CM, Elgart ML. Fungating pustular plaques in a patient with Graves’ disease: iododerma. Arch Dermatol 1994; 130: 786–7, 789-90

    PubMed  CAS  Article  Google Scholar 

  91. 91.

    Alpay K, Kurkcuoglu N. Iododerma: an unusual side effect of iodide ingestion. Pediatr Dermatol 1996; 13: 51–3

    PubMed  CAS  Article  Google Scholar 

  92. 92.

    Ricci C, Krasovec M, Frenk E. Amiodarone induced iododerma treated by cyclosporine. Ann Dermatol Venereol 1997; 124: 260–3

    PubMed  CAS  Google Scholar 

  93. 93.

    Miranda-Romero A, Sánchez-Sambucety P, Esquivias Gómez JI, et al. Vegetating iododerma with fatal outcome. Dermatology 1999; 198: 295–7

    PubMed  CAS  Article  Google Scholar 

  94. 94.

    Pranteda G, Grimaldi M, Salzetta M, et al. Vegetating iododerma and pulmonary eosinophilic infiltration: a simple co-occurrence? Acta Derm Venereol 2004; 84: 480–1

    PubMed  Google Scholar 

  95. 95.

    Paul AK, Al-Nahhas A, Ansari SM, et al. Skin eruptions following treatment with iodine-131 for hyperthyroidism: a rare and un-reported early/ intermediate side effect. Nucl Med Rev Cent East Eur 2005; 8: 125–7

    PubMed  Google Scholar 

  96. 96.

    Aydingöz IE, Göktay F, Serdar ZA, et al. Iododerma following sitz bath with povidone-iodine. Australas J Dermatol 2007; 48: 102–4

    PubMed  Article  Google Scholar 

  97. 97.

    Massé M, Falanga V, Zhou LH. Use of topical povidone-iodine resulting in an iododerma-like eruption. J Dermatol 2008; 35: 744–7

    PubMed  Article  Google Scholar 

  98. 98.

    Arditti J, Follana J, Bonerandi JJ, et al. Bromide vegetating skin diseases after treatment by a bromocalcic specialty. Eur J Toxicol Environ Hyg 1976; 9: 59–63

    PubMed  CAS  Google Scholar 

  99. 99.

    Smith SZ, Scheen SR. Bromoderma. Arch Dermatol 1978; 114: 458–9

    PubMed  CAS  Article  Google Scholar 

  100. 100.

    Roman P, Bourgeois-Droin C. Bromide-induced skin diseases. Ann Dermatol Venereol 1999; 126: 831–4

    PubMed  CAS  Google Scholar 

  101. 101.

    Maffeis L, Musolino MC, Cambiaghi S. Single-plaque vegetating bromoderma. J Am Acad Dermatol 2008; 58: 682–4

    PubMed  Article  Google Scholar 

  102. 102.

    Herxheimer K. Uber chlorakne [letter]. Münchener Medicinische Wochenschrift 1899; 46: 278

    Google Scholar 

  103. 103.

    Tindall JP. Chloracne and chloracnegens. J Am Acad Dermatol 1985; 13: 539–58

    PubMed  CAS  Article  Google Scholar 

  104. 104.

    McDonagh AJG, Gawkrodger DJ, Walker AE. Chloracne. Clin Exp Dermatol 1993; 18: 523–5

    PubMed  CAS  Article  Google Scholar 

  105. 105.

    Rodríguez-Pichardo A, Camacho F. Chloracne as a consequence of a family accident with chlorinated dioxins [letter]. J Am Acad Dermatol 1990; 22: 1121

    PubMed  Article  Google Scholar 

  106. 106.

    Soper LE, Vitez TS, Weinberg D. Metabolism of halogenated anaesthetic agents as a possible cause of acneiform eruptions. Anaesth Analg 1973; 52: 125–7

    CAS  Article  Google Scholar 

  107. 107.

    Guldager H. Halothane allergy as a cause of acne. Lancet 1987; 1: 1211–2

    PubMed  CAS  Article  Google Scholar 

  108. 108.

    Alagheband M, Engineer L. Lithium and halogenoderma. Arch Dermatol 2000; 136: 126–7

    PubMed  CAS  Article  Google Scholar 

  109. 109.

    Joynt RL. Dantrolene sodium: long term effects in patients with muscle spasticity. Arch Phys Med Rehabil 1976; 57: 212–7

    PubMed  CAS  Google Scholar 

  110. 110.

    Pembrocke AC, Sexena SR, Katiara M, et al. Acne induced by dantrolene. Br J Dermatol 1981; 104: 465–8

    Article  Google Scholar 

  111. 111.

    Mowbray M, Sinclair SA, Allan SJ. Severe acneiform eruption exacerbated by dantrolene sodium. Clin Exp Dermatol 2009; 34: 248–9

    PubMed  CAS  Article  Google Scholar 

  112. 112.

    Burkhart CG. Quinidine-induced acne. Arch Dermatol 1981; 117: 603–4

    PubMed  CAS  Article  Google Scholar 

  113. 113.

    Scott C, Staughton RC, Bunker CJ, et al. Acne vulgaris and acne rosacea as part of immune reconstitution disease in HIV-1 infected patients starting antiretroviral therapy. Int J STD AIDS 2008; 19: 493–5

    PubMed  Article  Google Scholar 

  114. 114.

    Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23: 5235–46

    Article  Google Scholar 

  115. 115.

    Busam KJ, Capoiece P, Motzer R, et al. Cutaneous side effects in cancer patients treated with the anti-epidermal growth factor receptor antibody C 225. Br J Dermatol 2001; 144: 1169–76

    PubMed  CAS  Article  Google Scholar 

  116. 116.

    Walon L, Gilbeau C, Lachapelle JM. Acneiform eruptions induced by cetuximab. Ann Dermatol Venereol 2003; 130: 443–6

    PubMed  CAS  Google Scholar 

  117. 117.

    Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004; 151: 238–41

    PubMed  CAS  Article  Google Scholar 

  118. 118.

    Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today 2005; 41: 107–27

    PubMed  CAS  Article  Google Scholar 

  119. 119.

    Hannoud S, Rixe O, Bloch J, et al. Skin signs associated with epidermal growth factor inhibitors. Ann Dermatol Venereol 2006; 133: 239–42

    PubMed  CAS  Article  Google Scholar 

  120. 120.

    Segaert S, Van Custem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425–33

    PubMed  CAS  Article  Google Scholar 

  121. 121.

    Osio A, Mateus C, Soria JC, et al. Cutaneous side-effects in patients on longterm treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 2009; 161: 515–21

    PubMed  CAS  Article  Google Scholar 

  122. 122.

    U.S. Department of Health and Human Services, National Institutes of Health,National Cancer Institute. Common terminology criteria for adverse events (CTCAE), version 4.0 published 28 May 2009; version 4.03 published 14 June 2010 [online]. Available from URL: (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf [Accessed 2011 Apr 6]

  123. 123.

    Scope A, Agero AL, Dusza AL, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25: 5390–6

    PubMed  CAS  Article  Google Scholar 

  124. 124.

    Deplanque G. CYTAR: a randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients [abstract no. 9019]. ASCO Annual Meeting; 2010 Jun 4-8; Chicago (IL)

  125. 125.

    Pichler WJ. Adverse side-effects to biological agents. Allergy 2006; 61: 912–20

    PubMed  CAS  Article  Google Scholar 

  126. 126.

    Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803–12

    PubMed  CAS  Article  Google Scholar 

  127. 127.

    Martín JM, Jordá E, Monteagudo C, et al. Follicular acneiform eruption induced by imatinib. J Eur Acad Dermatol Venereol 2006; 20: 1368–70

    PubMed  Article  Google Scholar 

  128. 128.

    Fleta-Asín B, Vañó-Galván S, Ledo-Rodríguez A, et al. Facial acneiform rash associated with sorafenib [letter]. Dermatol Online J 2009; 15: 7

    PubMed  Google Scholar 

  129. 129.

    Porta C, Paglino C, Imarisio I, et al. Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007; 7: 127–34

    PubMed  CAS  Article  Google Scholar 

  130. 130.

    Alexandrescu DT, Vaillant JG, Dasanu CA. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin Exp Dermatol 2007; 32: 71–4

    PubMed  CAS  Google Scholar 

  131. 131.

    Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161: 1045–51

    PubMed  CAS  Article  Google Scholar 

  132. 132.

    Nardone B, Nicholson K, Newman M, et al. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients. Clin Cancer Res 2010; 16: 4452–60

    PubMed  CAS  Article  Google Scholar 

  133. 133.

    Michot C, Guillot B, Dereure O. Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents. Dermatology 2010; 220: 49–50

    PubMed  Article  Google Scholar 

  134. 134.

    Keenan BP, Abuav R. Acneiform eruption in a patient receiving bevacizumab for glioblastoma multiforme [letter]. Arch Dermatol 2010; 146: 577

    PubMed  Article  Google Scholar 

  135. 135.

    Banerji U, Camidge DR, Verheul HM, et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 2010; 16: 1613–23

    PubMed  CAS  Article  Google Scholar 

  136. 136.

    Bassi E, Poli F, Charachon A, et al. Infliximab-induced acne: report of two cases. Br J Dermatol 2007; 156: 402–3

    PubMed  CAS  Article  Google Scholar 

  137. 137.

    Sladden MJ, Clarke PJ, Mitchell B. Infliximab-induced acne: report of a third case [letter]. Br J Dermatol 2008; 158: 172

    PubMed  CAS  Article  Google Scholar 

  138. 138.

    Sun G, Wasko CA, Hsu S. Acneiform eruption following anti-TNF-alpha treatment: a report of three cases. J Drugs Dermatol 2008; 7: 69–71

    PubMed  Google Scholar 

  139. 139.

    Ree AH, Dueland S, Folkvord S, et al. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 2010; 11: 459–64

    PubMed  CAS  Article  Google Scholar 

  140. 140.

    Pour L, Hajek R, Zdenek A, et al. Skin lesions induced by bortezomib. Haematologica 2005; 90 (12 Suppl.): ECR44

    Google Scholar 

Download references

Acknowledgments

No funding sources or financial disclosures/conflicts of interest to report. Aurélie Du-Thanh and Nicolas Kluger contributed equally to this work.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Prof. Bernard Guillot.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Du-Thanh, A., Kluger, N., Bensalleh, H. et al. Drug-Induced Acneiform Eruption. Am J Clin Dermatol 12, 233–245 (2011). https://doi.org/10.2165/11588900-000000000-00000

Download citation

Keywords

  • Acne
  • Erlotinib
  • Sirolimus
  • Aripiprazole
  • Isotretinoin